Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Vergniol

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|May 7, 2016
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver diseaseJérôme Boursier, Julien Vergniol, Anne Guillet, et al.
Journal of Hepatology|December 3, 2013
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)Thierry Poynard, Julien Vergniol, Yen Ngo, et al.
The American Journal of Gastroenterology|October 4, 2012
Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver diseaseVincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong, et al.
Journal of Hepatology|December 17, 2011
Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®Victor de Lédinghen, Vincent Wai-Sun Wong, Julien Vergniol, et al.
Hepatology (Baltimore, Md.)|January 27, 2010
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver diseaseVincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong, et al.
Journal of Hepatology|May 17, 2017
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameterVincent Wai-Sun Wong, Salvatore Petta, Jean-Baptiste Hiriart, et al.
Journal of Gastroenterology and Hepatology|October 31, 2015
Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver diseaseVictor de Lédinghen, Grace Lai-Hung Wong, Julien Vergniol, et al.
Hepatology (Baltimore, Md.)|September 18, 2016
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter valuesSalvatore Petta, Vincent Wai-Sun Wong, Calogero Cammà, et al.
The American Journal of Gastroenterology|June 7, 2019
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver DiseaseSalvatore Petta, Vincent Wai-Sun Wong, Elisabetta Bugianesi, et al.
Clinics and Research in Hepatology and Gastroenterology|June 25, 2020
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 studyAnthony Turpin, Thierry de Baere, Alexandra Heurgué, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|May 7, 2016
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver diseaseJérôme Boursier, Julien Vergniol, Anne Guillet, et al.
Journal of Hepatology|December 3, 2013
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)Thierry Poynard, Julien Vergniol, Yen Ngo, et al.
The American Journal of Gastroenterology|October 4, 2012
Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver diseaseVincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong, et al.
Journal of Hepatology|December 17, 2011
Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®Victor de Lédinghen, Vincent Wai-Sun Wong, Julien Vergniol, et al.
Hepatology (Baltimore, Md.)|January 27, 2010
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver diseaseVincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong, et al.
Journal of Hepatology|May 17, 2017
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameterVincent Wai-Sun Wong, Salvatore Petta, Jean-Baptiste Hiriart, et al.
Journal of Gastroenterology and Hepatology|October 31, 2015
Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver diseaseVictor de Lédinghen, Grace Lai-Hung Wong, Julien Vergniol, et al.
Hepatology (Baltimore, Md.)|September 18, 2016
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter valuesSalvatore Petta, Vincent Wai-Sun Wong, Calogero Cammà, et al.
The American Journal of Gastroenterology|June 7, 2019
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver DiseaseSalvatore Petta, Vincent Wai-Sun Wong, Elisabetta Bugianesi, et al.
Clinics and Research in Hepatology and Gastroenterology|June 25, 2020
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 studyAnthony Turpin, Thierry de Baere, Alexandra Heurgué, et al.
Pageof 6